Silexion Therapeutics Corp (SLXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,500 | -4,238 | -1,735 | -16,519 | -14,772 |
| Depreciation Amortization | 11 | 7 | 4 | 25 | 37 |
| Accounts payable and accrued liabilities | 17 | -237 | -207 | 610 | 479 |
| Other Working Capital | -704 | -1,097 | -824 | -1,580 | -633 |
| Other Operating Activity | 373 | 605 | 309 | 9,068 | 9,419 |
| Operating Cash Flow | $-7,803 | $-4,960 | $-2,453 | $-8,396 | $-5,470 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7 | -7 | -6 | -22 | -22 |
| Investing Cash Flow | $-7 | $-7 | $-6 | $-22 | $-22 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -696 | -696 | -696 | N/A | N/A |
| Common Stock Issued | 18,680 | 9,140 | 9,140 | 3,054 | 620 |
| Other Financing Activity | -2,123 | -1,207 | -1,012 | 2,050 | 2,300 |
| Financing Cash Flow | $15,861 | $7,237 | $7,432 | $5,104 | $2,920 |
| Exchange Rate Effect | 3 | 4 | -10 | -61 | -50 |
| Beginning Cash Position | 1,270 | 1,270 | 1,270 | 4,645 | 4,645 |
| End Cash Position | 9,324 | 3,544 | 6,233 | 1,270 | 2,023 |
| Net Cash Flow | $8,054 | $2,274 | $4,963 | $-3,375 | $-2,622 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,803 | -4,960 | -2,453 | -8,396 | -5,470 |
| Capital Expenditure | -7 | -7 | -6 | -22 | -22 |
| Free Cash Flow | -7,810 | -4,967 | -2,459 | -8,418 | -5,492 |